Target intelligence / Profile preview

Claudin-12 (CLDN12)

Target
CLDN12
Molecular classification
Tight junction protein, Integral membrane protein, Claudin family, Other
01

Overview

Claudin-12 is an atypical tight junction protein of the claudin family, encoded by the CLDN12 gene. It is an integral membrane protein contributing to paracellular barrier function, especially in epithelial and endothelial tissues. Claudin-12 is highly expressed in specific normal tissues such as the intestine, kidney, inner ear, and bladder epithelium. Its physiological roles include regulation of paracellular calcium transport—especially as part of the vitamin D-dependent absorption pathway—and maintaining epithelial polarity. CLDN12 expression is context-dependent and dysregulated in various cancers, sometimes promoting metastasis and chemoresistance, but may also act as a tumor suppressor in other settings. It has experimental value as a potential therapeutic target to modulate barrier function and inhibit tumor cell migration or myeloid-derived suppressor cell (MDSC) trafficking, and serves as a prognostic biomarker in several malignancies[1][2][3][4][5].

Other names
Claudin-12CLDN12claudin 12claudin-12
02

Mechanism of action

Not established for approved drugs; experimental antibodies and inhibitory peptides shown to interfere with CLDN12 function and tumor cell migration[1][3].

03

Biological functions

Maintenance of epithelial and endothelial barrier functionParacellular calcium transportRegulation of paracellular permeabilityCell polarity maintenanceSignal transductionCell migration (especially in cancer)Other
04

Disease associations

Cancer (including breast cancer, colon cancer, ovarian cancer, cervical cancer, laryngeal carcinoma)Deafness (autosomal recessive 29)Tumor metastasisPotential in immune cell transmigration in cancer immunosuppressionOther
05

Safety considerations

Potential off-target effects if broadly inhibiting tight junctions in normal tissuesAltering epithelial barrier integrity could impact tissue function or increase risk of non-specific toxicity, especially in tissues where CLDN12 is normally expressed[1][3]
06

Biomarkers

Prognostic biomarker in several cancers (breast, colorectal, cervical)Associated with drug resistance phenotype in ovarian cancerIndicator of vitamin D-dependent calcium absorption[1][4]

Beyond the preview

Go deeper on Claudin-12 (CLDN12).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Claudin-12 (CLDN12).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call